A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
Justin A. Chen(Cornell University), Edward Kim(University of California, Davis), Thomas J. Semrad(University of California, Davis), David R. Gandara(University of California, Davis), Kit Tam, Jasmine C. Huynh, Karen Kelly(Cancer Research Center), Tianhong Li(VA Northern California Health Care System), Ai‐Ming Yu(University at Buffalo, State University of New York), Chun-Yi Wu, Jonathan W. Riess(University of California Davis Medical Center), Nichole Mahaffey, Karen Matsukuma(Sacramento City College), Anthony Martinez, Philip C. Mack(UC Davis Comprehensive Cancer Center)
Cited by 7
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k